PRICE T ROWE ASSOCIATES INC /MD/ - INTELLIA THERAPEUTICS INC ownership

INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 369 filers reported holding INTELLIA THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 1.08 and the average weighting 0.2%.

Quarter-by-quarter ownership
PRICE T ROWE ASSOCIATES INC /MD/ ownership history of INTELLIA THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$64,797
-22.9%
2,049,220
-0.5%
0.01%
-25.0%
Q2 2023$84,028
+20.6%
2,060,491
+10.2%
0.01%
+20.0%
Q1 2023$69,687
+3.5%
1,869,761
-3.1%
0.01%
-9.1%
Q4 2022$67,315
-99.9%
1,929,355
+11.1%
0.01%
-31.2%
Q3 2022$97,218,000
-8.3%
1,737,260
-15.1%
0.02%
+23.1%
Q2 2022$105,970,000
-34.3%
2,047,331
-7.8%
0.01%
-18.8%
Q1 2022$161,318,000
-35.0%
2,219,871
+5.7%
0.02%
-27.3%
Q4 2021$248,345,000
-21.0%
2,100,348
-10.4%
0.02%
-26.7%
Q3 2021$314,520,000
-21.9%
2,344,538
-5.7%
0.03%
-18.9%
Q2 2021$402,588,000
+115.8%
2,486,491
+7.0%
0.04%
+94.7%
Q1 2021$186,552,000
+61.7%
2,324,490
+9.6%
0.02%
+58.3%
Q4 2020$115,376,000
+298.1%
2,120,883
+45.5%
0.01%
+300.0%
Q3 2020$28,985,000
+1.9%
1,458,005
+7.7%
0.00%
-25.0%
Q2 2020$28,447,000
+10059.6%
1,353,314
+13139.2%
0.00%
Q2 2018$280,000
-77.5%
10,222
-82.7%
0.00%
Q1 2018$1,243,00058,9400.00%
Other shareholders
INTELLIA THERAPEUTICS INC shareholders Q4 2021
NameSharesValueWeighting ↓
Discovery Value Fund 561,561$17,756,5599.73%
MPM BioImpact LLC 544,639$17,221,4854.60%
Casdin Capital, LLC 1,178,075$37,250,7324.12%
HIMENSION CAPITAL (SINGAPORE) PTE. LTD. 1,145,091$36,207,7773.72%
Atlas Venture Associates IX, LLC 10,000$316,2002.69%
Deep Track Capital, LP 2,000,000$63,240,0002.44%
ARK Investment Management 9,948,629$314,575,6382.41%
Merlin Capital, Inc 18,526$585,7922.19%
Orchard Capital Management, LLC 159,155$5,032,4811.86%
TANG CAPITAL MANAGEMENT LLC 397,600$12,572,1121.77%
View complete list of INTELLIA THERAPEUTICS INC shareholders